FDA Grants Fast Track Designation to VS-7375 for KRAS G12D-Mutated Advanced NSCLC
The FDA grants fast track designation to VS-7375 for KRAS G12D‑mutated advanced NSCLC.
The FDA has granted a fast‑track designation to VS‑7375, an oral KRAS G12D dual ON/OFF inhibitor, for adults with KRAS G12D‑mutated unresectable locally advanced or metastatic non‑small cell lung cancer (NSCLC) who have previously received platinum‑based chemotherapy and an anti‑PD‑L1 therapy.
KRAS G12D‑mutated NSCLC patients have no approved mutation‑specific therapies and have poor outcomes with standard care, highlighting an urgent unmet need.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT